Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Andrew Alan Nierenberg, M.D.

Co-Author

This page shows the publications co-authored by Andrew Nierenberg and Maurizio Fava.
Connection Strength

11.392
  1. A critical overview of the pharmacologic management of treatment-resistant depression. Psychiatr Clin North Am. 2007 Mar; 30(1):13-29.
    View in: PubMed
    Score: 0.360
  2. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol. 2003 Feb; 23(1):92-5.
    View in: PubMed
    Score: 0.271
  3. Nortriptyline for treatment-resistant depression. J Clin Psychiatry. 2003 Jan; 64(1):35-9.
    View in: PubMed
    Score: 0.270
  4. Body dysmorphic disorder in outpatients with major depression. J Affect Disord. 2002 May; 69(1-3):141-8.
    View in: PubMed
    Score: 0.258
  5. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry. 2000 Sep; 157(9):1423-8.
    View in: PubMed
    Score: 0.230
  6. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999 Apr; 60(4):221-5.
    View in: PubMed
    Score: 0.208
  7. Tachyphylaxis in major depressive disorder: A review of the current state of research. J Affect Disord. 2019 02 15; 245:488-497.
    View in: PubMed
    Score: 0.202
  8. Course and treatment of atypical depression. J Clin Psychiatry. 1998; 59 Suppl 18:5-9.
    View in: PubMed
    Score: 0.191
  9. Are neurovegetative symptoms stable in relapsing or recurrent atypical depressive episodes? Biol Psychiatry. 1996 Oct 15; 40(8):691-6.
    View in: PubMed
    Score: 0.175
  10. Cynicism, hostility, and suicidal ideation in depressed outpatients. J Nerv Ment Dis. 1996 Oct; 184(10):607-10.
    View in: PubMed
    Score: 0.175
  11. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry. 1995 Oct; 152(10):1500-3.
    View in: PubMed
    Score: 0.163
  12. Predictors of placebo response in bipolar depression. Int Clin Psychopharmacol. 2015 Mar; 30(2):59-66.
    View in: PubMed
    Score: 0.157
  13. Depression: addressing partial response after first-line antidepressant treatment. J Clin Psychiatry. 2014 Sep; 75(9):978-80.
    View in: PubMed
    Score: 0.151
  14. An exploratory study of combination buspirone and melatonin SR in major depressive disorder (MDD): a possible role for neurogenesis in drug discovery. J Psychiatr Res. 2012 Dec; 46(12):1553-63.
    View in: PubMed
    Score: 0.132
  15. The absence of depressive symptoms is not the presence of wellness: validation of the Clinical Positive Affect Scale. Aust N Z J Psychiatry. 2012 Dec; 46(12):1165-72.
    View in: PubMed
    Score: 0.132
  16. Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. Am J Psychiatry. 2012 Aug; 169(8):868-9.
    View in: PubMed
    Score: 0.131
  17. Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment. CNS Spectr. 2012 Jun; 17(2):76-86.
    View in: PubMed
    Score: 0.130
  18. Correlates and outcomes of depressed out-patients with greater and fewer anxious symptoms: a CO-MED report. Int J Neuropsychopharmacol. 2012 Nov; 15(10):1387-99.
    View in: PubMed
    Score: 0.125
  19. Response rates to fluoxetine in subjects who initially show no improvement. J Clin Psychiatry. 2011 Jul; 72(7):949-54.
    View in: PubMed
    Score: 0.121
  20. A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. J Clin Psychiatry. 2009 Dec; 70(12):1636-44.
    View in: PubMed
    Score: 0.107
  21. STAR*D: revising conventional wisdom. CNS Drugs. 2009 Aug; 23(8):627-47.
    View in: PubMed
    Score: 0.106
  22. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med. 2010 Jan; 40(1):41-50.
    View in: PubMed
    Score: 0.105
  23. A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. Eur Neuropsychopharmacol. 2008 Sep; 18(9):639-45.
    View in: PubMed
    Score: 0.098
  24. A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder. J Occup Environ Med. 2008 Apr; 50(4):428-36.
    View in: PubMed
    Score: 0.097
  25. Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. J Gen Intern Med. 2008 May; 23(5):551-60.
    View in: PubMed
    Score: 0.096
  26. Major depressive disorder with anger attacks and subcortical MRI white matter hyperintensities. J Nerv Ment Dis. 2007 Feb; 195(2):175-8.
    View in: PubMed
    Score: 0.090
  27. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. Psychiatry Res. 2007 Jan 15; 149(1-3):195-200.
    View in: PubMed
    Score: 0.089
  28. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 Nov; 163(11):1905-17.
    View in: PubMed
    Score: 0.088
  29. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006 Sep; 163(9):1519-30; quiz 1665.
    View in: PubMed
    Score: 0.087
  30. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry. 2006 Jul; 163(7):1161-72.
    View in: PubMed
    Score: 0.086
  31. Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine. Psychosomatics. 2006 Jul-Aug; 47(4):348-52.
    View in: PubMed
    Score: 0.086
  32. Family history of mood disorder and characteristics of major depressive disorder: a STAR*D (sequenced treatment alternatives to relieve depression) study. J Psychiatr Res. 2007 Apr-Jun; 41(3-4):214-21.
    View in: PubMed
    Score: 0.085
  33. Clinical and demographic factors associated with DSM-IV melancholic depression. Ann Clin Psychiatry. 2006 Apr-Jun; 18(2):91-8.
    View in: PubMed
    Score: 0.084
  34. Brain white-matter hyperintensities and treatment outcome in major depressive disorder. Br J Psychiatry. 2006 Feb; 188:180-5.
    View in: PubMed
    Score: 0.084
  35. Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part I). Psychiatry Res. 2005 Dec 30; 140(3):291-9.
    View in: PubMed
    Score: 0.083
  36. Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II). Psychiatry Res. 2005 Dec 30; 140(3):301-7.
    View in: PubMed
    Score: 0.082
  37. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry. 2005 Oct; 66(10):1326-30.
    View in: PubMed
    Score: 0.082
  38. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol. 2005 Oct; 25(5):441-7.
    View in: PubMed
    Score: 0.082
  39. An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry. 2006 Mar 15; 59(6):493-501.
    View in: PubMed
    Score: 0.082
  40. Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder. Psychosom Med. 2005 Sep-Oct; 67(5):703-6.
    View in: PubMed
    Score: 0.081
  41. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol. 2005 Aug; 25(4):336-41.
    View in: PubMed
    Score: 0.081
  42. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. J Clin Psychiatry. 2005 Aug; 66(8):1038-42.
    View in: PubMed
    Score: 0.081
  43. The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. Int J Neuropsychopharmacol. 2005 Dec; 8(4):523-8.
    View in: PubMed
    Score: 0.079
  44. Outcomes of recognizing depressed Chinese American patients in primary care. Int J Psychiatry Med. 2005; 35(3):213-24.
    View in: PubMed
    Score: 0.077
  45. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol. 2004 Dec; 24(6):661-4.
    View in: PubMed
    Score: 0.077
  46. Suicide risk management for the sequenced treatment alternatives to relieve depression study: applied NIMH guidelines. J Psychiatr Res. 2004 Nov-Dec; 38(6):583-9.
    View in: PubMed
    Score: 0.077
  47. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. J Clin Psychopharmacol. 2004 Oct; 24(5):507-11.
    View in: PubMed
    Score: 0.076
  48. Obesity among outpatients with major depressive disorder. Int J Neuropsychopharmacol. 2005 Mar; 8(1):59-63.
    View in: PubMed
    Score: 0.076
  49. Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment. Psychosomatics. 2004 Sep-Oct; 45(5):419-25.
    View in: PubMed
    Score: 0.076
  50. Serum cholesterol in the continuation phase of pharmacotherapy with fluoxetine in remitted major depressive disorder. J Clin Psychopharmacol. 2004 Aug; 24(4):467-9.
    View in: PubMed
    Score: 0.075
  51. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression. J Clin Psychiatry. 2004 Aug; 65(8):1090-5.
    View in: PubMed
    Score: 0.075
  52. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy. J Clin Psychiatry. 2004 Aug; 65(8):1096-8.
    View in: PubMed
    Score: 0.075
  53. Psychosocial functioning in patients with treatment resistant depression. Eur Psychiatry. 2004 Jun; 19(4):196-201.
    View in: PubMed
    Score: 0.074
  54. Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. Psychiatry Res. 2004 May 30; 126(3):287-90.
    View in: PubMed
    Score: 0.074
  55. Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression. Psychosomatics. 2004 May-Jun; 45(3):224-9.
    View in: PubMed
    Score: 0.074
  56. Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder. J Clin Psychiatry. 2004 Apr; 65(4):543-6.
    View in: PubMed
    Score: 0.074
  57. Illness beliefs of depressed Chinese American patients in primary care. J Nerv Ment Dis. 2004 Apr; 192(4):324-7.
    View in: PubMed
    Score: 0.074
  58. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry. 2004 Feb; 65(2):217-21.
    View in: PubMed
    Score: 0.073
  59. Quality of life assessments in major depressive disorder: a review of the literature. Gen Hosp Psychiatry. 2004 Jan-Feb; 26(1):13-7.
    View in: PubMed
    Score: 0.072
  60. Prevalence of major depressive disorder among Chinese-Americans in primary care. Gen Hosp Psychiatry. 2004 Jan-Feb; 26(1):24-30.
    View in: PubMed
    Score: 0.072
  61. Clinical and sociodemographic predictors of response to augmentation, or dose increase among depressed outpatients resistant to fluoxetine 20 mg/day. Acta Psychiatr Scand. 2003 Dec; 108(6):432-8.
    View in: PubMed
    Score: 0.072
  62. The impact of medical comorbidity on acute treatment in major depressive disorder. Am J Psychiatry. 2003 Dec; 160(12):2122-7.
    View in: PubMed
    Score: 0.072
  63. Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder. J Clin Psychiatry. 2003 Nov; 64(11):1357-61.
    View in: PubMed
    Score: 0.071
  64. Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive disorder. Ann Clin Psychiatry. 2003 Sep-Dec; 15(3-4):187-92.
    View in: PubMed
    Score: 0.071
  65. A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed. Int Clin Psychopharmacol. 2003 Sep; 18(5):293-6.
    View in: PubMed
    Score: 0.071
  66. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003 Jun; 26(2):457-94, x.
    View in: PubMed
    Score: 0.069
  67. Serum cholesterol and serotonergic function in major depressive disorder. Psychiatry Res. 2003 May 30; 118(2):137-45.
    View in: PubMed
    Score: 0.069
  68. Axis III disorders in treatment-resistant major depressive disorder. Psychiatry Res. 2003 May 30; 118(2):183-8.
    View in: PubMed
    Score: 0.069
  69. Somatic symptoms in treatment-resistant depression. Psychiatry Res. 2003 May 01; 118(1):39-45.
    View in: PubMed
    Score: 0.069
  70. Behavioral and emotional disturbances in the offspring of depressed parents with anger attacks. Psychother Psychosom. 2003 Mar-Apr; 72(2):102-6.
    View in: PubMed
    Score: 0.068
  71. Serum cholesterol in treatment-resistant depression. Neuropsychobiology. 2003; 47(3):146-51.
    View in: PubMed
    Score: 0.067
  72. Functioning and interpersonal relationships as predictors of response in treatment-resistant depression. Compr Psychiatry. 2003 Jan-Feb; 44(1):44-50.
    View in: PubMed
    Score: 0.067
  73. Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. J Clin Psychopharmacol. 2002 Oct; 22(5):474-80.
    View in: PubMed
    Score: 0.066
  74. Melancholia and axis II comorbidity. Compr Psychiatry. 2002 Sep-Oct; 43(5):331-5.
    View in: PubMed
    Score: 0.066
  75. The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. Ann Clin Psychiatry. 2002 Sep; 14(3):143-7.
    View in: PubMed
    Score: 0.066
  76. Treatment-resistant depression and Axis II comorbidity. Psychother Psychosom. 2002 Sep-Oct; 71(5):269-74.
    View in: PubMed
    Score: 0.066
  77. Personality disorders and depression. Psychol Med. 2002 Aug; 32(6):1049-57.
    View in: PubMed
    Score: 0.066
  78. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol. 2002 Aug; 22(4):379-87.
    View in: PubMed
    Score: 0.066
  79. Screening for major depression in Asian-Americans: a comparison of the Beck and the Chinese Depression Inventory. Acta Psychiatr Scand. 2002 Apr; 105(4):252-7.
    View in: PubMed
    Score: 0.064
  80. Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. Ann Clin Psychiatry. 2002 Mar; 14(1):33-8.
    View in: PubMed
    Score: 0.064
  81. Use of the Chinese version of the Beck Depression Inventory for screening depression in primary care. J Nerv Ment Dis. 2002 Feb; 190(2):94-9.
    View in: PubMed
    Score: 0.063
  82. NEO-FFI factor scores as predictors of clinical response to fluoxetine in depressed outpatients. Psychiatry Res. 2002 Jan 31; 109(1):9-16.
    View in: PubMed
    Score: 0.063
  83. A survey of prescribing practices in the treatment of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jan; 26(1):177-87.
    View in: PubMed
    Score: 0.063
  84. Use of the five-factory inventory in characterizing patients with major depressive disorder. Compr Psychiatry. 2001 Nov-Dec; 42(6):488-93.
    View in: PubMed
    Score: 0.062
  85. Treatment resistant depression and axis I co-morbidity. Psychol Med. 2001 Oct; 31(7):1223-9.
    View in: PubMed
    Score: 0.062
  86. Tryptophan depletion in SSRI-recovered depressed outpatients. Psychopharmacology (Berl). 2001 May; 155(2):123-7.
    View in: PubMed
    Score: 0.060
  87. Management of major depression in the primary care setting. Psychother Psychosom. 2001 Mar-Apr; 70(2):103-7.
    View in: PubMed
    Score: 0.059
  88. T3 blood levels and treatment outcome in depression. Int J Psychiatry Med. 2001; 31(4):367-73.
    View in: PubMed
    Score: 0.059
  89. A survey of prescribing preferences in the treatment of refractory depression: recent trends. Psychopharmacol Bull. 2001; 35(3):150-6.
    View in: PubMed
    Score: 0.059
  90. Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation. Prostaglandins Leukot Essent Fatty Acids. 2021 01; 164:102219.
    View in: PubMed
    Score: 0.058
  91. Nutrition and depression: focus on folate. Nutrition. 2000 Jul-Aug; 16(7-8):544-6.
    View in: PubMed
    Score: 0.057
  92. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can J Psychiatry. 2000 Jun; 45(5):476-81.
    View in: PubMed
    Score: 0.056
  93. Fenfluramine challenge in unipolar depression with and without anger attacks. Psychiatry Res. 2000 Apr 24; 94(1):9-18.
    View in: PubMed
    Score: 0.056
  94. Anxiety disorders in major depression. Compr Psychiatry. 2000 Mar-Apr; 41(2):97-102.
    View in: PubMed
    Score: 0.055
  95. Predictive factors of diagnostic conversion from major depressive disorder to bipolar disorder in young adults ages 19-34: A nationwide population study in South Korea. J Affect Disord. 2020 03 15; 265:52-58.
    View in: PubMed
    Score: 0.055
  96. Tridimensional personality questionnaire and treatment response in major depressive disorder: a negative study. J Affect Disord. 2000 Jan-Mar; 57(1-3):241-7.
    View in: PubMed
    Score: 0.055
  97. Compounds containing cytosolic choline in the basal ganglia: a potential biological marker of true drug response to fluoxetine. Am J Psychiatry. 1999 Oct; 156(10):1638-40.
    View in: PubMed
    Score: 0.054
  98. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. J Clin Psychiatry. 1999 Sep; 60(9):580-3.
    View in: PubMed
    Score: 0.054
  99. Dysfunctional attitudes and poor problem solving skills predict hopelessness in major depression. J Affect Disord. 1999 Sep; 55(1):45-9.
    View in: PubMed
    Score: 0.054
  100. Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. J Clin Psychopharmacol. 1999 Aug; 19(4):329-35.
    View in: PubMed
    Score: 0.053
  101. Axis I and Axis II disorder comorbidity in unipolar depression with anger attacks. J Affect Disord. 1999 Jan-Mar; 52(1-3):217-23.
    View in: PubMed
    Score: 0.051
  102. An open trial of oral sildenafilin antidepressant-induced sexual dysfunction. Psychother Psychosom. 1998; 67(6):328-31.
    View in: PubMed
    Score: 0.048
  103. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry. 1997 Dec; 154(12):1760-2.
    View in: PubMed
    Score: 0.047
  104. Major depressive subtypes and treatment response. Biol Psychiatry. 1997 Oct 01; 42(7):568-76.
    View in: PubMed
    Score: 0.047
  105. Social phobia, avoidant personality disorder and atypical depression: co-occurrence and clinical implications. Psychol Med. 1997 May; 27(3):627-33.
    View in: PubMed
    Score: 0.046
  106. Folate, vitamin B12, and homocysteine in major depressive disorder. Am J Psychiatry. 1997 Mar; 154(3):426-8.
    View in: PubMed
    Score: 0.045
  107. A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia. Psychopharmacol Bull. 1997; 33(1):101-3.
    View in: PubMed
    Score: 0.045
  108. Hostility changes following antidepressant treatment: relationship to stress and negative thinking. J Psychiatr Res. 1996 Nov-Dec; 30(6):459-67.
    View in: PubMed
    Score: 0.044
  109. Patterns of personality disorder comorbidity in early-onset versus late-onset major depression. Am J Psychiatry. 1996 Oct; 153(10):1308-12.
    View in: PubMed
    Score: 0.044
  110. Gender differences in Axis I comorbidity among depressed outpatients. J Affect Disord. 1996 Jun 05; 38(2-3):129-33.
    View in: PubMed
    Score: 0.043
  111. Attention deficit hyperactivity disorder in childhood among adults with major depression. Psychiatry Res. 1996 Jun 01; 62(3):213-9.
    View in: PubMed
    Score: 0.043
  112. Reduced Venous Blood Basophil Count and Anxious Depression in Patients with Major Depressive Disorder. Psychiatry Investig. 2016 May; 13(3):321-6.
    View in: PubMed
    Score: 0.043
  113. Fluoxetine treatment of anger attacks: a replication study. Ann Clin Psychiatry. 1996 Mar; 8(1):7-10.
    View in: PubMed
    Score: 0.042
  114. Outpatients with DSM-III-R versus DSM-IV melancholic depression. Compr Psychiatry. 1996 Jan-Feb; 37(1):37-9.
    View in: PubMed
    Score: 0.042
  115. Relationship between placebo response rate and clinical trial outcome in bipolar depression. J Psychiatr Res. 2016 Mar; 74:38-44.
    View in: PubMed
    Score: 0.041
  116. Anxiety symptoms are linked to new-onset suicidal ideation after six months of follow-up in outpatients with major depressive disorder. J Affect Disord. 2015 Nov 15; 187:183-7.
    View in: PubMed
    Score: 0.041
  117. Near-Infrared Transcranial Radiation for Major Depressive Disorder: Proof of Concept Study. Psychiatry J. 2015; 2015:352979.
    View in: PubMed
    Score: 0.040
  118. Social adjustment does not predict depressive relapse during continuation fluoxetine therapy. J Affect Disord. 1995 May 17; 34(2):73-7.
    View in: PubMed
    Score: 0.040
  119. Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. J Clin Psychiatry. 1995 Feb; 56(2):52-5.
    View in: PubMed
    Score: 0.039
  120. Thyroid stimulating hormone and serum, plasma, and platelet brain-derived neurotrophic factor during a 3-month follow-up in patients with major depressive disorder. J Affect Disord. 2014 Dec; 169:112-7.
    View in: PubMed
    Score: 0.038
  121. Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders. J Affect Disord. 2014 Oct; 168:439-51.
    View in: PubMed
    Score: 0.037
  122. Serum lipids, recent suicide attempt and recent suicide status in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jun 03; 51:113-8.
    View in: PubMed
    Score: 0.036
  123. Conditional probability of response or nonresponse of placebo compared with antidepressants or St John's Wort in major depressive disorder. J Clin Psychopharmacol. 2013 Dec; 33(6):827-30.
    View in: PubMed
    Score: 0.036
  124. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. J Clin Psychiatry. 2013 Jul; 74(7):e636-41.
    View in: PubMed
    Score: 0.035
  125. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations. J Clin Psychiatry. 2012 Jul; 73(7):967-76.
    View in: PubMed
    Score: 0.032
  126. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study. J Clin Psychiatry. 2011 Oct; 72(10):1322-32.
    View in: PubMed
    Score: 0.031
  127. Concise Health Risk Tracking scale: a brief self-report and clinician rating of suicidal risk. J Clin Psychiatry. 2011 Jun; 72(6):757-64.
    View in: PubMed
    Score: 0.030
  128. Concise Associated Symptoms Tracking scale: a brief self-report and clinician rating of symptoms associated with suicidality. J Clin Psychiatry. 2011 Jun; 72(6):765-74.
    View in: PubMed
    Score: 0.030
  129. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. J Affect Disord. 2011 Oct; 133(3):467-76.
    View in: PubMed
    Score: 0.030
  130. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011 Jul; 168(7):689-701.
    View in: PubMed
    Score: 0.030
  131. Psychoticism and paranoid ideation in patients with nonpsychotic major depressive disorder: prevalence, response to treatment, and impact on short- and long-term treatment outcome. CNS Spectr. 2010 Aug; 15(8):515-21.
    View in: PubMed
    Score: 0.029
  132. Assuring that double-blind is blind. Am J Psychiatry. 2010 Mar; 167(3):250-2.
    View in: PubMed
    Score: 0.028
  133. Do atypical features affect outcome in depressed outpatients treated with citalopram? Int J Neuropsychopharmacol. 2010 Feb; 13(1):15-30.
    View in: PubMed
    Score: 0.026
  134. Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry. 2009 May; 166(5):599-607.
    View in: PubMed
    Score: 0.026
  135. The response of psychotic-like symptoms to fluoxetine monotherapy in non-psychotic major depressive disorder. Nord J Psychiatry. 2009; 63(5):420-5.
    View in: PubMed
    Score: 0.026
  136. Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR(*)D trial. Depress Anxiety. 2009; 26(7):612-21.
    View in: PubMed
    Score: 0.026
  137. Family history of depression and therapeutic outcome: findings from STAR*D. J Clin Psychiatry. 2009 Feb; 70(2):185-95.
    View in: PubMed
    Score: 0.025
  138. Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. J Clin Psychiatry. 2008 Dec; 69(12):1847-55.
    View in: PubMed
    Score: 0.025
  139. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry. 2008 Aug; 65(8):870-80.
    View in: PubMed
    Score: 0.025
  140. Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report. J Clin Psychiatry. 2008 Aug; 69(8):1246-56.
    View in: PubMed
    Score: 0.025
  141. Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder. Biol Psychiatry. 2008 Jun 15; 63(12):1127-34.
    View in: PubMed
    Score: 0.024
  142. Effect of age at onset on the course of major depressive disorder. Am J Psychiatry. 2007 Oct; 164(10):1539-46.
    View in: PubMed
    Score: 0.023
  143. A detailed examination of cytokine abnormalities in Major Depressive Disorder. Eur Neuropsychopharmacol. 2008 Mar; 18(3):230-3.
    View in: PubMed
    Score: 0.023
  144. Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. Am J Psychiatry. 2007 Aug; 164(8):1189-97.
    View in: PubMed
    Score: 0.023
  145. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry. 2007 May; 164(5):739-52.
    View in: PubMed
    Score: 0.023
  146. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006 Sep; 163(9):1531-41; quiz 1666.
    View in: PubMed
    Score: 0.022
  147. Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry. 2006 Sep; 163(9):1542-8.
    View in: PubMed
    Score: 0.022
  148. Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry. 2006 Sep 01; 60(5):432-5.
    View in: PubMed
    Score: 0.021
  149. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006 Mar 23; 354(12):1231-42.
    View in: PubMed
    Score: 0.021
  150. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006 Mar 23; 354(12):1243-52.
    View in: PubMed
    Score: 0.021
  151. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006 Jan; 163(1):28-40.
    View in: PubMed
    Score: 0.021
  152. A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic. Ann Clin Psychiatry. 2005 Jul-Sep; 17(3):161-5.
    View in: PubMed
    Score: 0.020
  153. Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo. Int J Neuropsychopharmacol. 2005 Jun; 8(2):215-21.
    View in: PubMed
    Score: 0.019
  154. The prevalence and clinical correlates of anger attacks during depressive episodes in bipolar disorder. J Affect Disord. 2004 Apr; 79(1-3):291-5.
    View in: PubMed
    Score: 0.018
  155. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004 Feb; 25(1):119-42.
    View in: PubMed
    Score: 0.018
  156. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry. 2003 Jun 01; 53(11):1028-42.
    View in: PubMed
    Score: 0.017
  157. Strategies for treatment of SSRI-associated sexual dysfunction: a survey of an academic psychopharmacology practice. Harv Rev Psychiatry. 2002 Mar-Apr; 10(2):109-14.
    View in: PubMed
    Score: 0.016
  158. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. J Clin Psychiatry. 2000 Jun; 61(6):403-8.
    View in: PubMed
    Score: 0.014
  159. Patterns of axis I comorbidity in early-onset versus late-onset major depressive disorder. Biol Psychiatry. 1999 Jul 15; 46(2):202-11.
    View in: PubMed
    Score: 0.013
  160. Outcome definitions and predictors in depression. Psychother Psychosom. 1998 Jul-Oct; 67(4-5):266-70.
    View in: PubMed
    Score: 0.012
  161. Basal ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry. 1997 Apr 15; 41(8):837-43.
    View in: PubMed
    Score: 0.011
  162. Consumption of alcohol, nicotine, and caffeine among depressed outpatients. Relationship with response to treatment. Psychosomatics. 1996 Nov-Dec; 37(6):518-22.
    View in: PubMed
    Score: 0.011
  163. Are study dropouts different from completers? Biol Psychiatry. 1996 Oct 01; 40(7):668-70.
    View in: PubMed
    Score: 0.011
  164. Hypochondriacal concerns in depressed outpatients. Psychosom Med. 1996 Jul-Aug; 58(4):314-20.
    View in: PubMed
    Score: 0.011
  165. Patterns of improvement in depressive symptoms with fluoxetine treatment. Psychopharmacol Bull. 1995; 31(2):223-6.
    View in: PubMed
    Score: 0.010
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.